Overview

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Status:
Active, not recruiting

Trial end date:
2026-10-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy results in an improvement of metastasis-free survival.

Phase:

Phase 3

Details

Lead Sponsor:

Aragon Pharmaceuticals, Inc.

Treatments:

Bicalutamide